ORPRELBA
Live / Applied — Third extension granted (statement of use) (as of 10 Feb 2026)
What this means for you
Not registered yet, but its 30 Jan 2024 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 98382833
- Mark type
- Stylized text
- Filed
- 30 Jan 2024
- Published for opposition
- 13 Aug 2024
- Attorney of record
- Danielle Rivera
Goods and services
- Class 005 — Pharmaceuticals: Human pharmaceutical preparations for the prevention and treatment of viral diseases, auto-immune and inflammatory diseases, alloimmune diseases, cardiovascular and pulmonary diseases, central nervous system diseases, peripheral neurological system diseases, pain, dermatologic diseases, gastro-intestinal diseases, infectious-related diseases, metabolic diseases, oncologic diseases, ophthalmic diseases, respiratory diseases, hematological diseases, urological diseases, maternal fetal disorders, digital ulcers
Owner
- Johnson & Johnson, New Brunswick, NJ, US
- Johnson & Johnson, New Brunswick, NJ, US
Prosecution history
- 11 Feb 2026 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Feb 2026 — SOU EXTENSION 3 GRANTED
- 10 Feb 2026 — SOU EXTENSION 3 FILED
- 10 Feb 2026 — SOU TEAS EXTENSION RECEIVED
- 20 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 19 Sept 2025 — SOU EXTENSION 2 GRANTED
- 19 Sept 2025 — SOU EXTENSION 2 FILED
- 19 Sept 2025 — SOU TEAS EXTENSION RECEIVED
- 27 Mar 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 26 Mar 2025 — SOU EXTENSION 1 GRANTED
- 26 Mar 2025 — SOU EXTENSION 1 FILED
- 26 Mar 2025 — SOU TEAS EXTENSION RECEIVED
- 08 Oct 2024 — NOA E-MAILED - SOU REQUIRED FROM APPLICANT
- 13 Aug 2024 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 13 Aug 2024 — PUBLISHED FOR OPPOSITION